Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Deciphera Pharmaceuticals Inc
(NQ:
DCPH
)
25.59
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Deciphera Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
February 01, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
January 18, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
What 4 Analyst Ratings Have To Say About Deciphera Pharmaceuticals
November 20, 2023
Via
Benzinga
Earnings Preview: Deciphera Pharmaceuticals
August 08, 2023
Via
Benzinga
The Latest Analyst Ratings for Deciphera Pharmaceuticals
May 04, 2023
Via
Benzinga
Recap: Deciphera Pharmaceuticals Q1 Earnings
May 03, 2023
Via
Benzinga
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
January 08, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18
January 05, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit
November 29, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
November 07, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals' Investigational Drug Shows Encouraging Response Rates In Rare Type Of Cancer
October 30, 2023
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced top-line results from the MOTION Phase 3 study of vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT)
Via
Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
October 30, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results
October 30, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT
October 30, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 15, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
August 21, 2023
Biotech stocks may offer some of the most explosive opportunities on the market. Here are three with major catalysts nearing.
Via
InvestorPlace
3 Under-the-Radar Biotech Stocks to Buy in 2023
August 19, 2023
All three biotech companies focus on oncology therapies.
Via
The Motley Fool
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Why Shares of Deciphera Pharmaceuticals Rose This Week
August 11, 2023
The company's shares rose after the company reported second-quarter earnings.
Via
The Motley Fool
Deciphera Pharmaceuticals Sees Renewed Competitive Edge After Theseus Pan-KIT Discontinuation: Analyst
August 10, 2023
Stifel upgraded Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) to Buy from Hold, with a price target of $20 from $14, after reevaluating the competitive landscape for the 2L GIST market.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
August 10, 2023
Via
Benzinga
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday
August 10, 2023
Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on...
Via
Benzinga
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
August 09, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer
August 03, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023
August 02, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
May 25, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
May 23, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
May 08, 2023
From
Deciphera Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.